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Abstract
Background: Alterations in the extracellular matrix (ECM) can affect host-tumor interactions and
tumor growth and metastasis. Tissue transglutaminase (TG2, EC 2.3.2.13), a calcium-dependent
enzyme that catalyzes covalent cross-linking of proteins, can render the ECM highly stable and
resistant to proteolytic degradation. So we determined whether TG2 expression in a tumor or
nontumor (stroma) environment could affect the process of metastasis. Two hundred archived
samples from patients with breast cancer were studied for the TG2 expression. Also, in an in vitro
model the invasive behavior of MDA-MB-231 cells in the presence or absence of exogenous TG2
was determined.
Results: Tumors associated with negative nodes showed significantly higher expression of TG2 in
the stroma (P < 0.001). TG2 in the stroma was catalytically active, as revealed by the presence of
isopeptide cross-links. Pretreatment of Matrigel with catalytically active TG2 resulted in strong
inhibition of invasion of MDA-MB-231 cells through the Matrigel Transwell filters.
Conclusion:  TG2-induced alterations in the ECM could effectively inhibit the process of
metastasis. Therefore, selective induction of catalytically active TG2 at the site of tumor may offer
promising approach for limiting the metastasis.
Background
Despite significant advances in the treatment of primary
breast cancer, predicting and preventing metastasis
remains a daunting clinical challenge. To make progress
in this area, it is imperative to understand the molecular
mechanisms that regulate the progression from a primary
tumor to metastatic disease.
Metastasis is a multistep process that involves intravasa-
tion, adhesion to a blood vessel wall, extravasation, infil-
tration, and the proliferation of cancer cells in the target
tissue [1]. Many of these steps require interaction between
tumor cells and the extracellular matrix (ECM). For exam-
ple, the ECM can modulate tumorcell growth by binding
to and storing cytokines, it can promote cell attachment
and migration by providing a stable foundation, and it
can support cell growth and survival by interacting with
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cell-surface receptors and activating appropriate signaling
pathways [2,3].
Several lines of evidence have suggested that tissue trans-
glutaminase (TG2, EC 2.3.2.13) plays an important role
in stabilizing the ECM by cross-linking its component
proteins and rendering it resistant to mechanical and pro-
teolytic degradation [4-7]. TG2, a member of the Ca2+-
dependent family of mammalian enzymes, catalyzes irre-
versible cross-linking of proteins by inserting highly stable
ε(γ-glutamyl)lysine bonds between them [5,8,9]. Several
ECM proteins, such as fibronectin, vitronectin, collagen,
fibrin, laminin, osteonectin, and osteopontin, can serve as
substrates in TG2-catalyzed cross-linking reactions [4,10-
12]. Moreover, in various fibrotic disorders, such as pul-
monary fibrosis, renal fibrosis, and atherosclerosis
increased expression of TG2 has been observed, and its
ability to cross-link ECM proteins has been implicated in
facilitating the deposition of a new ECM and making it
resistant to metalloproteinases [12-16]. In addition to its
direct role in promoting the accumulation of the ECM,
TG2 has been implicated in the storage and activation of
transforming growth factor-beta (TGF-β) [17], a proin-
flammatory cytokine that is involved in the synthesis of
various ECM proteins and inhibitors of metalloprotein-
ases [18,19]. The ability of TG2 to affect the physicochem-
ical properties of the ECM may influence the invasive
properties of tumor cells by modulating cell-matrix inter-
actions or by facilitating the assembly of the matrix and
tissue remodeling.
In view of these facts and other observations that modifi-
cation of the ECM can affect the growth of both normal
and cancerous mammary epithelial cells and the processes
of angiogenesis and tumor metastasis [20-22], we specu-
lated that TG2 expression in the stroma of the host can
affect breast cancer progression. To test this theory, we
searched for such a correlation in tumor and stroma spec-
imens in a total 200 samples from patients with early-
stage breast cancer. Our findings suggested that TG2
expression in the stroma was associated with an absence
of lymph node metastasis in patients with breast cancer.
The results of our in vitro study further supported this link
and suggested that TG2-mediated modification of the
ECM could render it less susceptible to invasion by tumor
cells. Taken together, these findings suggest that TG2 is a
good candidate for therapeutic use to prevent progression
from a primary tumor to metastatic disease in patients
with breast cancer.
Results
Of the 200 samples studied, only 189 were evaluable
(Table 1). Patients without lymph node metastasis (n =
95) were followed for a median of 4 years after diagnosis.
Two of these patients experienced disease recurrence, and
4 died. Patients with lymph node metastasis (n = 94) were
followed for a median of 3.2 years after diagnosis. Ten of
these patients experienced disease recurrence, and 2 died.
A typical pattern of TG2 expression in mammary tumor
samples is shown in Fig. 1. Tumor samples showed either
high TG2 expression that was predominantly restricted to
the stroma surrounding the tumor (Fig. 1A &1B) or in
some cases converse was true; tumors expressed high lev-
els of TG2, but the stroma surrounding the tumor showed
little or no TG2 expression (Fig. 1C and 1D). In few
patient samples (approximately 12%) high TG2 expres-
sion was observed in both the tumor and the surrounding
stroma (Fig. 1E and 1F). Similarly, some samples
expressed little (≤1+) or no TG2 in the tumor or the
stroma (Fig. 1G and 1H).
The association of TG2 expression in tumors and stroma
with node-negative or -positive status is presented in
Table 1: TG2 expression in tumor and stroma tissues of patients with breast cancer
TG2 in tumor TG2 in stroma
Total 0 1+ 2+ 3+ p* 0 1+ 2+ 3+ P*
Tumor samples 1 8 9 8 43 73 33 5 8 55 22 82 4
Node status
Negative 95 46(48) 17(18) 17(18) 15(16) 24(25) 33(35) 20(21) 18(19)
Positive 94 38(41) 20(21) 16(17) 20(21) 61(65) 19(20) 8(9) 6(6)
0.28 <0.001
Age (yrs)
<50 53 21(39) 11(21) 11(21) 10(19) 22(41) 11(21) 21(21) 9(17)
>=50 136 63(46) 26(19) 22(16) 25(19) 63(46) 41(30) 17(13) 15(11)
0.51 0.14
* Cochran-Armitage trend test
The numbers in parenthesis indicate the percentages of total number of patients in that row.Molecular Cancer 2005, 4:33 http://www.molecular-cancer.com/content/4/1/33
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Table 1. There was no evidence that TG2 expression in
tumor cells differed between node-negative or node-posi-
tive samples. Nevertheless, there was strong evidence that
tumors associated with negative nodes had a significantly
higher TG2 expression in the stroma (P < 0.001). With
regard to the association of TG2 expression in tumors and
stroma with age, there was no evidence of a difference in
younger (<50 yrs) or older (>50 yrs) patient populations.
To further delineate the importance of TG2 expression in
the stroma and its possible implications in the modula-
tion of metastatic disease, we used an in vitro Matrigel
Transwell invasion assay with a human breast cancer cell
line MDA-MB-231. Under our experimental conditions,
MDA-MB-231 cells were highly invasive, as determined by
the number of cells that invaded through the Matrigel
Transwell filters (Fig. 2A). However, pretreatment of the
Matrigel with catalytically active TG2 (in the presence of
Ca2+) strongly inhibited the invasion of MDA-MB-231
cells through the Matrigel Transwell filters. Under identi-
cal conditions when the enzyme was rendered inactive by
eliminating Ca2+ from the reaction mixture, the number
of cells that invaded was not much different from that
seen in the control wells (coated with Matrigel that had
been preincubated with 5-mM Ca2+ but without TG2).
TG2-mediated inhibition of tumor cell invasion was dose-
dependent and could be observed by pretreating the
Matrigel contents with as little as 1 µg of TG2. At 6 µg, TG2
inhibited the invasion of MDA-MB-231 cells by more
than 80% (Fig. 2B). The inhibition of cell invasion
through TG2-pretreated Matrigels was most likely due to
the crosslinking of component proteins into high molec-
ular weight scaffolds (Fig. 2C). The TG2-induced
crosslinks are known to exhibit resistance to proteases and
thus may pose a barrier against protease-induced invasion
of cancer cells. Indeed, MDA-MB-231 cells produce active
proteases, such as MMP-1 and MMP-2 as revealed by
zymography and RT-PCR analysis (Fig. 2D). TG2 by itself,
either in the presence or in absence of Ca2+, did not exert
any noticeable effect on cell viability or growth of MDA-
MB-231 cells (data not shown). These results suggest that
active cross-linking of the Matrigel proteins by TG2 is
effective in preventing the invasion of tumor cells.
Next, we sought to determine whether TG2 in the stroma
of node-negative patients with breast cancer was catalyti-
cally active. To accomplish this, we studied the presence of
ε(γ-glutamyl)lysine isopeptide, the product of TG2-cata-
lyzed protein cross-linking reactions, in a few selected
samples. The results (Fig. 3) confirmed strong positivity of
the stroma for TG2 expression in selected node-negative
patient samples (red fluorescence). Importantly, the
expression of TG2 in stroma was closely associated with
the presence of isopeptide bonds, as revealed by strong
immunofluorescence staining with the anti-isopeptide
TG2 expression in tumor tissue samples from patients with  breast cancer Figure 1
TG2 expression in tumor tissue samples from patients with 
breast cancer. Paraffin-embedded tissues from the primary 
tumors were retrieved from the Tumor Tissue Bank in the 
Department of Pathology at The University of Texas M. D. 
Anderson Cancer Center. The tissue sections were proc-
essed for immunostaining as described in Materials and Meth-
ods. One hundred samples each from patients with or 
without lymph node metastasis were studied and independ-
ently scored by a pathologist and a laboratory technician for 
TG2 expression. The figure shows the extent of TG2 expres-
sion in the primary tumor cells and the stroma surrounding 
the tumor from eight representative patients. a and b, tumor 
samples from representative patients (14% of patients) in 
which TG2 expression was mainly localized in the stroma; c 
and d, tumor samples from representative patients (23% of 
patients) in which TG2 expression was mainly localized in the 
tumor; e and f, TG2 expression in some patients' tumor sam-
ples (13% of patients) was observed both in the tumor and 
the stroma; g and h, half of all patients (50%) showed almost 
a complete lack of TG2 in the tumor and the stroma. The 
TG2-positive cells in g and h were endothelial cells that had 
high constitutive TG2 expression.Molecular Cancer 2005, 4:33 http://www.molecular-cancer.com/content/4/1/33
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TG2 inhibits the invasion of MDA-MD-231 cells through a Matrigel-coated Transwell membrane Figure 2
TG2 inhibits the invasion of MDA-MD-231 cells through a Matrigel-coated Transwell membrane. A, Matrigel contents were 
incubated with buffer alone (control) or buffer containing the purified guinea pig liver TG2 protein (6 µg/0.75 ml) in the pres-
ence (TG2 + Ca2+) or absence (TG2 alone) of 5 mM Ca2+ at 37°C for 15 minutes before being coated onto the Transwell 
membranes. The MDA-MB-231 cells were compared for their ability to invade through the TG2-pretreated or untreated 
Matrigel-Transwell membranes. Representative fields with cells that migrated under the membrane were photographed. B, 
Matrigels (0.75 ml) containing increasing amounts of the purified TG2 protein were preincubated (37°C, 15 minutes) with 5 
mM Ca2+. Another tube containing Matrigel plus 6 µg of TG2 protein was incubated in parallel, but without Ca2+, to serve as 
control. Matrigel contents pretreated with various amounts of TG2 were layered over the Transwell membranes and com-
pared for their ability to support the invasion of MDA-MB-231 cells. Ten fields were counted randomly under the microscope 
for the number of cells that had migrated through the Matrigel and were plotted as an average number of cells ± SD per field. 
C, Equal volumes of Matrigel (0.75 ml) were incubated under conditions described in legend B with buffer alone or buffer con-
taining varying concentrations of purified TG2 in the presence (+) or absence (-) of 5 mM Ca2+. Forty µl reactants, each were 
fractionated on SDS-PAGE. The gel was stained and viewed for TG2-induced changes in protein bands after destaining in meth-
anol/acetic acid solution. The thin arrow indicates a prominent band that disappears in the presence of an enzymatically active 
TG2; whereas thick arrow indicates the appearance of a prominent band in the presence of active TG2. D, Basal levels of MMP-
1 and MMP-2 in MDA-MB-231 cells as determined by zymogram performed on the supernatants collected from cultured cells 
(80% confluent in 6-well plate, incubated in 1 ml serum-free medium overnight) or by RT-PCR, using MMP-1 specific primers, 
as described in Materials and Methods.Molecular Cancer 2005, 4:33 http://www.molecular-cancer.com/content/4/1/33
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antibody (green fluorescence). The expression of TG2 in
the stroma, in general, closely resembled the isopeptide
staining (Fig. 3), suggesting that the two antigens closely
associate in the stroma surrounding the tumor. These
results suggest that, in some patients, TG2 can localize
extracellularly and effectively cross-link ECM proteins,
thereby rendering the ECM resistant to invasion by tumor
cells.
Discussion
Major findings to emerge from this study are: in some
patients with breast cancer, tumor and nontumor
(stroma) environments express increased levels of TG2; in
the stroma, TG2 protein exists in a catalytically active con-
figuration, leading to cross-linking of the ECM proteins;
and TG2-catalyzed cross-linking of ECM proteins may
mitigate the migration of cancer cells to distant sites.
TG2 is a multifunctional protein that can affect the ECM
and its interaction with cells. Both the extracellular cross-
linking and intracellular signaling activities of TG2 can
considerably modulate cell-matrix interactions [7]. We
previously observed that TG2 expression was up-regulated
in drug-resistant and metastatic breast cancer cells and cell
lines [23-28]. The increased expression of TG2 in drug-
resistant and metastatic breast cancer cells was linked to
their increased resistance to apoptosis, owing to the fact
that TG2 in these cells closely associates with β integrins
and thus may promote cell survival signaling [28-30]. The
primary objective of this study was to determine whether
higher levels of TG2 in breast cancer cells were associated
with node involvement and development of aggressive
tumors. We found no evidence that TG2 tumor staining
differed between tumor samples associated with negative
or positive node status. These results are in agreement
with those of a previous study that revealed a negative cor-
relation between TG2 transcript expression and nodal sta-
tus in patients with breast cancer [31]. However, in
another report, Jiang et al. observed that lymph node
involvement and development of aggressive phenotype in
breast cancer tumors was associated with increased
expression of TG2 transcript and decreased levels of TG3
and TG7 transcript expression [32]. Similarly, another
group has reported a marked increase in TG2 expression
in the intraductal and invasive human breast cancer cells
[33]. Taken together, these observations suggest that
transglutaminases' repertoire is altered during breast can-
cer development and progression. Therefore, further stud-
ies are warranted with larger cohort of patients to
determine the prognostic significance of transglutami-
nases in the progression and development of metastatic
disease in patients with breast cancer.
More important, the results of our study suggest that TG2
expression in the stroma is strongly associated with node-
negative status in patients with breast cancer. A similar
increase in TG2 expression in the stroma surrounding the
tumor was observed by Haroon et al. in subcutaneously
implanted rat mammary tumors [34]. Treatment of these
tumors with enzymatically active TG2 significantly
delayed the tumor growth when compared with the
tumors treated with catalytically inactive TG2 mutant. On
the basis of these observations the authors concluded that
TG2 might constitute a distinct part of the host response
against growing tumor and by crosslinking the compo-
nent proteins, it may stabilize the ECM and affect the
tumor growth [34].
TG2 expression in the stroma is closely associated with the  formation of isopeptide bonds Figure 3
TG2 expression in the stroma is closely associated with the 
formation of isopeptide bonds. Tissue sections from 3 
selected patients with breast cancer that showed high TG2 
expression in the stroma were incubated simultaneously with 
rabbit anti-TG2 antibody and mouse anti-isopeptide mono-
clonal antibody. Anti-mouse IgG Alexa 488 and goat anti-rab-
bit IgG Alexa 546 were used as secondary antibodies to 
localize the presence of TG2 (A, C, E) and isopeptide (B, D, 
F), respectively. In a control experiment (G, H), a tissue sam-
ple lacking TG2 expression in the tumor and the stroma was 
used in a similar way (two primary and 2 secondary antibod-
ies) to determine the specificity of the antigen-antibody 
reactions.Molecular Cancer 2005, 4:33 http://www.molecular-cancer.com/content/4/1/33
Page 6 of 8
(page number not for citation purposes)
It is possible that local injury caused by the growing tumor
may elicit host's response and induce cytokines produc-
tion that in turn may promote wound healing and restrict
the invasion of cells by producing new or stable ECM [35].
Indeed, TG2 is capable of cross-linking several constituent
proteins in the ECM, which can render the ECM more
resistant to proteases and mechanical disruptions [4-6].
TG2 can also enhance stability and strengthen the ECM by
its ability to facilitate the activation of tumor growth fac-
tor-beta [17]. Thus, TG2-mediated alterations may render
the ECM more amenable to tumor growth and resistant to
proteases [36-38]. Indeed, our in vitro data shown in fig-
ure 2 clearly supported this contention and suggested that
TG2-mediated crosslinking of component proteins ren-
dered the matrigel resistant to invasion by MDA-MB-231
cells regardless of the fact that these cells actively pro-
duced matrix metalloproteinases (MMP) such as MMP-1
and MMP-2.
In conclusion, our findings suggest that increased expres-
sion of TG2 in the stroma represents a part of the host
response to a growing tumor in an attempt to restrict
tumor growth and prevent it from spreading to distant
sites. However, the ability of tumor cells to produce pro-
teases and other factors that could render TG2 inactive
may overwhelm the ability of TG2 to inhibit growth and
prevent metastasis. Indeed, TG2 has been shown to be a
good substrate for MMP-2-like proteases that are abun-
dantly produced by metastatic tumors [39,40]. Future
studies to selectively enhance the production of active
TG2 at the site of tumor growth may offer promising
approaches to limiting tumor growth and metastasis.
Methods
Cell Lines and Tumor Tissues
Human breast cancer cell line MDA-MB-231 was pur-
chased from American Type Culture Collection (Rock-
ville, MD) and cultured by standard methods. Tumor
samples from 200 patients with early-stage breast cancer
diagnosed between 1979 and 2002 were obtained from
the archives of the Pathology Department of The Univer-
sity of Texas M. D. Anderson Cancer Center after approval
by the Institutional Review Board for the Welfare of
Human Subjects. All the selected patients had tumors
ranging from 1 cm to 2 cm in largest diameter. Samples
were selected for inclusion to yield 100 tumor samples
that were associated with lymph node invasion and 100
tumor samples that were not associated with lymph node
invasion.
Invasion Assay
The invasive behavior of MDA-MB-231 cells in the pres-
ence or absence of exogenous TG2 was determined in vitro
by counting how many cells invaded through Matrigel-
coated Transwell polycarbonate membrane inserts, as
described previously [41,42]. Briefly, Transwell inserts
with a pore size of 12 µm were coated with 0.78 mg/ml
Matrigel in cold, serum-free medium. In some cases, the
Matrigel was preincubated (37°C for 15 minutes) with
varying concentrations of purified TG2 protein (Sigma-
Aldrich Chemical Co., St. Louis, MO) in the presence or
absence of 5 mM Ca2+  before being coated onto the
inserts. Also, Matrigel samples (40 µl aliquots) pretreated
with varying concentrations of TG2 in the presence or
absence of Ca2+ were subjected to 7% SDS-PAGE. The gel
was stained with Coomassie brilliant blue and destained
in a acetic acid and methanol solution before visualizing
the changes in protein bands as a consequence of TG2-
mediated crosslinking.
Cells were recovered by trypsinization and washed once
with serum-free medium. The cell pellets were resus-
pended in serum-free medium, and 0.5 ml of the cell sus-
pension (0.5 × 106 cells) was added to duplicate wells.
After incubation for 48 hours, the cells that passed
through the filter were stained using a Hema-3 stain kit
(Fisher Scientific, Houston, TX), and the cells in 10 ran-
dom fields were counted under a microscope.
Matrix Metalloproteinases (MMP)
Basal expression of MMP-1 and MMP-2 in MDA-MB-231
cells was determined by gelatin-substrate gel zymography
as described [41]. Briefly, the supernatant from MDA-MB-
231 cultured cells was subjected under nonreducing con-
ditions to gelatin impregnated (0.1%; w/v) SDS-PAGE.
The gel was washed several times to remove the SDS and
incubated in buffer containing 5 mM CaCl2 plus 1 µM
ZnCl2 for 24–48 h at 37°C. The gel was stained with
Coomassie brilliant blue and destained. Proteolytic activ-
ity was visualized as clear bands (zones of gelatin degrada-
tion) against the blue background of stained gelatin.
For RT-PCR, total RNA was isolated from MDA-MB-231
cells in Trizol reagent (Invitrogen, Life technologies, CA)
and cDNA was synthesized from 5 µg of total RNA using
Superscript reverse transcriptase (Life Technologies, Inc)
as per the manufacturer's instructions. cDNA was sub-
jected to PCR (GeneAmp PCR System 9700, Applied Bio-
systems) using MMP-1 specific, 5'-
CGACTCTAGAAACACAAGAGCAAGA-3' (sense) and 5'-
AAGGTTAGCTTACTGTCACACGCTT-3'(antisense) prim-
ers. PCR consisted of 30 cycles was carried out at the fol-
lowing conditions: 95°C for 5 min, 30 cycles of 95°C for
30 sec, annealing at 58°C for 1 min and elongation at
72°C for 2 min. PCR products were analyzed on 1% aga-
rose gel and visualized under UV light after staining with
ethidium bromide.Molecular Cancer 2005, 4:33 http://www.molecular-cancer.com/content/4/1/33
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Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded tumor
samples (5 µm thick) were heated to 60°C and dehy-
drated in xylene and graded alcohols. Antigen retrieval
was performed with 0.01 M citrate buffer at pH 6.0 for 20
minutes in a 95°C steam bath. Slides were allowed to cool
for 20 minutes at room temperature, followed by repeated
rinsing with 0.1 M phosphate-buffered saline (PBS, pH
7.4) containing 0.1% Tween 20 (PBS-T). Endogenous per-
oxidase activity was quenched with 3% hydrogen peroxi-
dase. Each incubation step was conducted at room
temperature and was followed by three sequential washes
(5–10 minutes each) in PBS-T. Sections were incubated
with anti-TG2 monoclonal antibodies, CUB-7401 (Neo-
markers, Fremont, CA) overnight at 4°C, followed by
incubation for 30 minutes each with biotinylated second-
ary antibody and peroxidase-labeled streptavidin. Anti-
gen-antibody reactions were detected by exposure to
3,3'diaminobenzidine and hydrogen peroxide chro-
mogen substrate (Vector Labs, Burlingame, CA) for 3–5
minutes. Slides were counterstained with hematoxylin
and mounted. The negative controls were incubated with
nonimmune mouse immunoglobulin g (IgG) in place of
the primary antibody. The immunostained slides were
examined under the light microscope and scored (with
values of 0, 1+, 2+, or 3+) independently by two research-
ers in the laboratory.
Confocal Microscopy
Paraffin-embedded tissue sections from selected tumor
samples were deparaffinized, washed 3 times with PBS,
and blocked with 5% normal goat serum in PBS for 1
hour. The sections were immunostained by an indirect
method using primary rabbit anti-TG2 (Neomarkers, Fre-
mont, CA) and anti-isopeptide monoclonal Ab422
(Abcam, Cambridge, MA) antibodies. The anti-mouse IgG
Alexa 488 and goat anti-rabbit IgG Alexa 546 (both from
Molecular Probes, Eugene, OR) were used as the second-
ary antibodies. The immunostained sections were
mounted in 80% glycerol and 20% PBS and viewed under
the Zeiss Laser Scanning Microscope 510 (Carl Zeiss
MicroImaging, Inc., Thornwood, NY) for taking the digital
images. Appropriate controls, including mouse and rabbit
IgG in place of the primary antibodies and either primary
antibody alone along with both the secondary antibodies
were included to determine the specificity of the reaction.
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